Skip to content

A randomized, controlled clinical study on the effect of repeated intranasal insulin administration on postoperative delirium and serum miRNA490-3P and neurog2 in elderly patients with radical esophagectomy

A randomized, controlled clinical study on the effect of repeated intranasal insulin administration on postoperative delirium and serum miRNA490-3P and neurog2 in elderly patients with radical esophagectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056907
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-02-25
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

control group:Saline

Sponsors

The General Hospital of Western Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age =60 years; 2.ASA grade I~III; 3.BMI=28kg/m2; 4.planned to undergo radical esophagectomy under general anesthesia; 5.signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are contraindicated for intranasal administration (such as nasal cavity defects or lesions); 2. Have hypertension and diabetes in the past; Have a history of insulin allergy; Have a history of alcoholism; 3. Unable to communicate before operation (coma, deep dementia or language disorder, severe visual and hearing impairment); 4. The MMSE score is too low [illiteracy<17 points, primary school level<20 points, secondary school level (including technical secondary school)<24 points]; 5. History of serious heart, liver and kidney disease, nervous system disease or mental disease; 6. Withdrawal criteria: insulin was used by other means than nasal route during the test; 7. Perform operation again within 3 days after operation; 8. Unexpected adverse events (such as drug allergy, anesthesia and surgical accidents); 9. The patient lost the follow-up.

Design outcomes

Primary

MeasureTime frame
Total incidence of POD in 3 days;miRNA-490-3P;Neurog2;

Secondary

MeasureTime frame
age;gender;body mass index;Educational level;Operation time;ASA classification;Preoperative hemoglobin concentration;Intraoperative blood loss;Intraoperative blood transfusion;NRSIscale;Coefficient of variation of blood glucose;

Countries

China

Contacts

Public ContactHuang Qingqing
970327481@qq.com+86 15283017764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026